Qianjiang Yongan Pharmaceutical Co Ltd (002365) — Financial Flexibility Index
Qianjiang Yongan Pharmaceutical Co Ltd (002365) has a Financial Flexibility Index of 0.28x as of September 2025. Free cash flow of CN¥70.03 Million (operating CF CN¥58.18 Million minus capex CN¥11.85 Million) represents 0% of total liabilities (CN¥247.20 Million). Also explore Qianjiang Yongan Pharmaceutical Co Ltd equity growth rate to track the company's year-over-year net asset growth rate.
Financial Flexibility Index
Free Cash Flow
Total Liabilities
Capital Expenditures
Qianjiang Yongan Pharmaceutical Co Ltd Financial Flexibility Index (2006–2024)
Historical Financial Flexibility Index trend for Qianjiang Yongan Pharmaceutical Co Ltd across 19 annual periods. Check Qianjiang Yongan Pharmaceutical Co Ltd PP&E and investment ratio to assess the company's strategic physical and investment asset allocation.
Annual Financial Flexibility Index for Qianjiang Yongan Pharmaceutical Co Ltd (2006–2024)
Year-by-year free cash flow to debt coverage for Qianjiang Yongan Pharmaceutical Co Ltd. For the full company profile including market capitalisation, see 002365 company net worth.
| Year | Flexibility Index | Free Cash Flow (CNY) | Operating CF | Total Liabilities | YoY Change |
|---|---|---|---|---|---|
| 2024 | 0.84x | CN¥223.76 Million | CN¥105.71 Million | CN¥266.55 Million | ▼ -31.3% |
| 2023 | 1.22x | CN¥365.00 Million | CN¥244.26 Million | CN¥298.85 Million | ▼ -26.9% |
| 2022 | 1.67x | CN¥536.35 Million | CN¥387.28 Million | CN¥321.17 Million | ▲ +233.2% |
| 2021 | 0.50x | CN¥164.86 Million | CN¥101.81 Million | CN¥328.95 Million | ▼ -43.6% |
| 2020 | 0.89x | CN¥311.07 Million | CN¥206.66 Million | CN¥349.92 Million | ▼ -40.3% |
| 2019 | 1.49x | CN¥373.94 Million | CN¥239.55 Million | CN¥251.14 Million | ▼ -17.5% |
| 2018 | 1.81x | CN¥583.52 Million | CN¥314.02 Million | CN¥323.11 Million | ▼ -12.7% |
| 2017 | 2.07x | CN¥486.79 Million | CN¥197.32 Million | CN¥235.23 Million | ▲ +59.7% |
| 2016 | 1.30x | CN¥124.66 Million | CN¥84.53 Million | CN¥96.22 Million | ▲ +3.3% |
| 2015 | 1.25x | CN¥104.73 Million | CN¥70.61 Million | CN¥83.50 Million | ▲ +41.9% |
| 2014 | 0.88x | CN¥69.95 Million | CN¥19.26 Million | CN¥79.14 Million | ▼ -33.8% |
| 2013 | 1.34x | CN¥163.57 Million | CN¥63.65 Million | CN¥122.50 Million | ▼ -18.5% |
| 2012 | 1.64x | CN¥190.93 Million | CN¥70.75 Million | CN¥116.59 Million | ▼ -49.7% |
| 2011 | 3.26x | CN¥339.26 Million | CN¥91.23 Million | CN¥104.13 Million | ▲ +67.0% |
| 2010 | 1.95x | CN¥148.58 Million | CN¥44.06 Million | CN¥76.14 Million | ▲ +65.4% |
| 2009 | 1.18x | CN¥82.41 Million | CN¥36.43 Million | CN¥69.83 Million | ▼ -38.6% |
| 2008 | 1.92x | CN¥230.66 Million | CN¥158.47 Million | CN¥120.04 Million | ▼ -0.8% |
| 2007 | 1.94x | CN¥121.85 Million | CN¥61.08 Million | CN¥62.89 Million | ▲ +83.6% |
| 2006 | 1.06x | CN¥48.79 Million | CN¥31.11 Million | CN¥46.24 Million | — |